Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2021 Financial Results
Earnings Call Scheduled for 8:00 a.m. ET on February 25, 2021
News provided by
Share this article
Share this article
HONG KONG, Feb. 19, 2021 /PRNewswire/ Global Cord Blood Corporation (NYSE: CO) (the Company ), China s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial results for the third quarter and first nine months of fiscal year 2021 on Wednesday, February 24, 2021, after the U.S. market close.
The Company will host a conference call at 8:00 a.m. ET on Thursday, February 25, 2021 to discuss its financial performance and give a brief overview of the Company s recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through the Company s IR website at http://ir.globalco
BEIJING (dpa-AFX) - Global Cord Blood Corporation (CO) said the company's Board and the board of Cordlife have mutually agreed to discontinue any further discussions regarding the Cordlife proposal.
Databridgemarketresearch.com Present “
Cord Blood & Cell Banking Market– Industry Trends and Forecast to 2027” new report to its research database. The research report released by Data Bridge Market research provides the market segmentation based on type, market size, Product launches and applications. It identifies the global adoption of the products as one of the growth factors, driven by the availability of the product. The global research report gives the brief summary of the leading players operating in the market, their product offering, key developments, investments feasibility and returns. This
Cord Blood & Cell Banking Market report which is outcome of the ultimate dedication of industry experts, has an abundance of data that can profit anybody, regardless of their business or academic interest.
Arbitrage funds may have further options available to maximise the value of their position in companies seeking to avail themselves of the Cayman Islands merger regime. In the recent article published by the Association of Insolvency and Restructuring Advisors the upward trajectory in share appraisal litigation in Cayman Islands was considered. This momentum is attributable to a number of factors but certainly fund managers will note that the discounted cash flow (DCF) (and indeed other income-based company valuation methodologies) can still prevail in Cayman. These types of actions have now proved by far the preferred remedy for shareholders who are dissatisfied with a merger or consolidation in the Cayman Islands. However, this is not the only remedy available to minority shareholders. The authors of this article are aware of other instances in the Cayman Islands where minority shareholders have issued proceedings to seek to prevent a merger from taking place and propose why we are
Global stem cell banking market 21
The Global stem cell banking market research report released by Data Bridge Market research provides the market segmentation based on type, market size, Product launches and applications. It identifies the global adoption of the products as one of the growth factors, driven by the availability of the product. The global research report gives the brief summary of the leading players operating in the market, their product offering, key developments, investments feasibility and returns. This Global stem cell banking market report which is outcome of the ultimate dedication of industry experts, has an abundance of data that can profit anybody, regardless of their business or academic interest.